Posted by Michael Wonder on 29 Mar 2024
Korean drug for metabolism-related steatohepatitis gets FDA’s fast track designation
28 March 2024 - D&D Pharmatech said Thursday that DD01, an injectable treatment for metabolic-associated steatohepatitis (MASH) being developed by the company, has received fast-track designation from the U.S. FDA.
This is the second MASH treatment developed by a Korean company to receive the FDA’s fast track designation.
